Pharmacyclics
Janssen reveals positive results from longest follow-up of Imbruvica
December 7, 2016Research and Development AbbVie, Cilag, Janssen, Pharmacyclics, imbruvica
Janssen used the 5th Annual American Society of Hematoly Meeting and Exposition to reveal that a five-year study of Imbruvica …
AbbVie buys Pharmacyclics in $21 billion deal
March 5, 2015Sales and Marketing AbbVie, Humira, Johnson and Johnson, Pharmacyclics, adalimumab, imbruvica
AbbVie has secured Californian biotech Pharmacyclics and beat Johnson & Johnson to gain control of blockbuster blood cancer therapy Imbruvica in …
AstraZeneca buys biotech Definiens
November 4, 2014Research and Development, Sales and Marketing AstraZeneca, Janssen, MedImmune, Pharmacyclics, binnig, definiens
AstraZeneca has strengthened its oncology capabilities with the acquisition of Definiens, a German company that has pioneered cancer imaging and …
Roche and Pharmacyclics agree leukaemia pact
October 17, 2014Research and Development, Sales and Marketing BMS, CLL, Cancer, Gazyva, Pharmacyclics, Roche, imbruvica, leukaemia
Pharmacyclics’s cancer drug Imbruvica will be tested in combination with Roche’s Gazyva in a new partnership announced by the firms. …
BMS, Pharmacyclics and Janssen collaborate on cancer
October 14, 2014Research and Development, Sales and Marketing BMS, Janssen, Pharmacyclics, imbruvica, opdivo
Bristol-Myers Squibb, Pharmacyclics and Janssen are to collaborate on clinical trials combining BMS’s cancer drug Opdivo (nivolumab) with Janssen and …
Imbruvica boost for Pharmacyclics
January 8, 2014Sales and Marketing Janssen, Pharmacyclics, imbruvica
Pharmacyclics and Janssen Biotech have received a huge boost as a late-stage trial of their first-in-class, oral blood cancer drug …
Janssen/Pharmacyclics gain FDA nod for Imbruvica
November 14, 2013Sales and Marketing FDA, Janssen, Pharmacyclics, Revlimid, Velcade
The FDA has approved Janssen and Pharmacyclics’ Imbruvica to treat patients with mantle cell lymphoma (MCL), a rare and aggressive …
Janssen inks $150m deal for blood cancer drug
December 12, 2011Research and Development, Sales and Marketing Janssen, Pharmacyclics
Janssen biotech has signed a licensing deal with Pharmacyclics for its investigational blood cancer drug. The firm has paid $150 …
Latest content
